FuturAqua to invest HUF 400 mln in cancer research
FuturAqua, a company listed on the Budapest Stock Exchange, will provide HUF 400 million for the clinical research and development of a Hungarian cancer drug as part of its cooperation with HYD Pharma, the latter company told Hungarian news agency MTI.
FuturAqua wants to finance its contribution partly from R&D funding and partly by raising funds on the capital market. Shareholders at FuturAquaʼs general meeting on Tuesday unanimously approved the cooperation.
Clinical tests on patients with chronic lymphoid leukemia (CLL) are expected to start in the first quarter of 2017, with the first official results due at the end of 2018, HYD Pharma said.
HYD Pharma conducts research and development of deuterium-depleted products.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.